Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: a randomized phase II proof-of-concept study
Phase 2
Suspended
- Conditions
- esophageal adenocarcinomaesophageal cancer10017991
- Registration Number
- NL-OMON54869
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 48
Inclusion Criteria
- Histologically proven adenocarcinoma of the esophagus or gastroesophageal
junction.
- Surgically resectable (<T4b, N0 or N+, M0)
- Patient is fit for surgery
Exclusion Criteria
- Past (within 5 years) or current history of malignancy other than entry
diagnosis interfering with prognosis of esophageal cancer, not including
superficial and adequately treated skin and cervical malignancies.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint is pathological response to chemoradiotherapy according to<br /><br>the Mandard criteria. </p><br>
- Secondary Outcome Measures
Name Time Method